Rising stars: David Gibson – ‘There are so many great new technologies and medicines with potential to make a difference to populations and treatment pathways but key challenges remain in regulating them’ Sophie Chan[email protected]9 February 2024ProfileLife Sciences Yearbook 2024 David Gibson, senior associate at McDermott Will & EmeryWhy did you decide to specialise in life sciences law, and what’s the best thing about being a life sciences lawyer?Your limit of 1 article in 30 days is up. Please login for full access or subscribe. Corporate users - click here for simple access (no password needed). For more information, please contact [email protected] Related ContentMore in this categoryThirty firms win roles in revamped £820m government legal panel – with three new appointments‘There’s definitely competition around rates’ – Clifford Chance and Linklaters match Cravath bonuses for US associatesCohen & Gresser follows McDermott in eyeing up external investmentM&A perspectives: Melissa FogartyM&A perspectives: Jennifer BethlehemM&A perspectives: Lorenzo CorteSponsored thought leadership: China life sciences – Transaction insights and notable industry trendsThe Legal 500 view: Healthy competitionLife Sciences Yearbook 2024 – Editor’s letter